羧甲司坦口服液联合氟替美维吸入粉雾剂治疗支气管哮喘的效果

打开文本图片集

[Abstract]Objective：To exploreand analyze the clinical effect of Carbocysteine Oral Solution combined withFluticasone Furoate，Umeclidinium Bromideand Vilanterol Trifenatate Powder for Inhalation in patients with bronchialasthma.Method：A total of 8O patients diagnosed with bronchial asthmaadmited totheDepartment of Respiratory Medicine of Beijing Huairou Hospital from Januaryto December 2O24 were selected and divided into the observation group and the control group through the double-blind digital table protocol， with 4O cases in each group.Both groups received basic symptomatic treatment intervention. On this basis，the control group was treatedwithFluticasoneFuroate，UmeclidiniumBromideandVilanterolTrifenatatePowderforInhalation，whilethe observation group was treated with Carbocysteine Oral Solution combined with Fluticasone Furoate， Umeclidinium Bromideand Vilanterol Trifenatate Powder for Inhalation.The treatment course was2 weeks.The asthma control test （ACT） scores，serum factor levels，sputum and mucus secretion indicators，and medication safety of the two groups were compared.Result： Compared with the control group，the observation group had higher ACT score after treatment （ P <0.05）. After treatment， levels of interferon-gamma （IFN- γ ）， leukotriene B4 （LTB4）， IL-6，and intercellular adhesion molecule-1 （ICAM-1） in theobservation group were allower than those in the control group 0 P <0.05）.After treatment，the observation group showed less daily sputum volume，lower sputum viscosity，and sputum mucin 5ac levels compared with the control group （ P <0.05）. There was no statistically significant difference in the total incidence of adverse reactions between the two groups （ P >0.05）. Conclusion： The combined treatment of Carbocysteine Oral SolutionandFluticasone Furoate，Umeclidinium Bromideand VilanterolTrifenatate Powder for Inhalation can efectively control the condition，relieve inflammatory responses，and reduce sputum secretion. The safety of medication is relatively high.

[KeyWords]Carbocysteine Oral Solution Fluticasone Furoate， Umeclidinium Bromide and Vilanterol TrifenatatePowder for Inhalation Bronchial asthma

支气管哮喘为临床常见呼吸道慢性病，病变特征是肺部小气道长期伴有炎症反应，使呼吸道处于高反应状态，极易发生肿胀，患者在发病状态下主要表现为喘息、呼吸急促、咳嗽、胸闷等[]。（剩余5731字）